Results 81 to 90 of about 4,155 (158)

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy. [PDF]

Pharmacoecon Open, 2023
Cortesi PA, Fornari C, Gisondi P, Iannone F, Antonazzo IC, Aloisi E, Fiocchi M, Ritrovato D, Mantovani LG.   +8 more
europepmc   +1 more source

Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. [PDF]

Rheumatol Ther, 2023
Kiltz U, Kishimoto M, Walsh JA, Sampaio-Barros P, Mittal M, Saffore CD, Wung P, Ganz F, Biljan A, Poddubnyy D.   +9 more
europepmc   +1 more source

Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons. [PDF]

Rheumatol Ther, 2023
Akkoç N, Arteaga CH, Auteri SE, Betts M, Fahrbach K, Kim M, Kiri S, Neupane B, Gaffney K, Mease PJ.   +9 more
europepmc   +1 more source

Test-retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis. [PDF]

RMD Open, 2021
Boel A, Navarro-Compán V, van der Heijde D.   +2 more
europepmc   +1 more source

Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years. [PDF]

Rheumatol Ther, 2022
Aparicio M, Guillén-Astete CA, López-Medina C, Sastre C, Rodríguez Martínez FJ.   +4 more
europepmc   +1 more source

The validity and reliability of quality of life questionnaires in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and meta-analysis. [PDF]

Health Qual Life Outcomes, 2022
He Q, Luo J, Chen J, Yang J, Yao C, Xu C, Tao Q.   +6 more
europepmc   +1 more source

An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis

Drug Design, Development and Therapy, 2016
Julien Paccou, René-Marc Flipo Department of Rheumatology, Lille University Hospital, Lille, France Abstract: Golimumab (Simponi®) is a fully human tumor necrosis factor α inhibitor (TNFi) antibody administered subcutaneously.
Paccou J, Flipo RM
doaj  

Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol. [PDF]

Arthritis Res Ther, 2021
Maksymowych WP, Kumke T, Auteri SE, Hoepken B, Bauer L, Rudwaleit M.   +5 more
europepmc   +1 more source

Risk factors for progression of juvenile-onset non-radiographic axial spondyloarthritis to juvenile-onset ankylosing spondylitis: a nested case-control study. [PDF]

RMD Open, 2021
Li HG, Wang DM, Shen FC, Huang SX, Hou ZD, Lin L, Xiao ZY.   +6 more
europepmc   +1 more source

Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study. [PDF]

ACR Open Rheumatol, 2022
Robinson PC, Maksymowych WP, Gensler LS, Hall S, Rudwaleit M, Hoepken B, Bauer L, Kumke T, Kim M, de Peyrecave N, Deodhar A.   +10 more
europepmc   +1 more source